A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: a GOG study

Alvarez, Ronald

97 - Featured Poster
A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: a GOG study

Monday, March 24, 2014: 7:16 AM

Room 13-16 (Tampa Convention Center)

R. D. Alvarez¹, M. Sill², S. A. Davidson³, C. Muller⁴, D. P. Bender⁵, R. DeBernardo⁶, K. Behbakht³ and W. K. Huh¹
¹University of Alabama at Birmingham, Birmingham, AL, ²Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, ³University of Colorado Denver, Aurora, CO, ⁴University of New Mexico, Albuquerque, Albuquerque, NM, ⁵University of Iowa Hospitals and Clinics, Iowa City, IA, ⁶Cleveland Clinic, Cleveland, OH

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

97 - Featured Poster
A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: a GOG study

97 - Featured Poster A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: a GOG study

97 - Featured Poster
A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: a GOG study